Pharmacoepidemiology and Pharmacovigilance in Drug-Therapy: New Issues, Challenges, and Applications
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (5 March 2021)
Special Issue Editor
Special Issue Information
Dear Colleagues,
Drug therapy produces both positive (therapeutic effect) and negative effects (adverse events). Pharmacoepidemiology helps us to understand the uses and effects of medicines in populations, aims at improving the appropriateness and safety of drug therapy. This process of understanding the uses and effects of medicines in pharmacoepidemiology is supported by pharmacologic basis and thus bridging pharmacology and epidemiology. Pharmacoepidemiology and pharmacovigilance play a critical role in relating to the collection, assessment, and monitoring of drug therapy and adverse drug events. Because of its importance, many countries have established services to conduct regular audits and to publish reports on the use of medicines and adverse effects at the regional or national level. There is a general acceptance or consensus that pharmacoepidemiology and pharmacovigilance can play a crucial role in providing critical information about drug therapy but there are challenges concerning the methodology and reporting of results. During the novel coronavirus 2019 (COVID-19) pandemic, we have witnessed a surge of interest in drug repositioning or repurposing and this provides an opportunity for researchers to use pharmacoepidemiologic approaches in evaluating drug therapy. These approaches are extensively employed to understand the uses and effects of various drugs used in the treatment and management of COVID-19.
This special issue has the aim to summarize the state-of-the-art, and the latest findings published in the pharmacoepidemiology and drug safety field, as well as to elucidate future directions. The journal invites both reviews and original articles shedding light on the challenges and opportunities in pharmacoepidemiology and pharmacovigilance approaches. Topics include the application of pharmacoepidemiology in understanding the uses and effects of drugs in communicable and non-communicable diseases, challenges in conducting large pharmacoepidemiologic studies, methods used in reporting of adverse events, etc.
Dr. Syed Hasan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacoepidemiology
- pharmacovigilance
- adverse events reporting approaches
- challenges for pharmacoepidemiology
- opportunities for pharmacoepidemiology
